Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vical Inc (NASDAQ:VICL)

2.32
Delayed Data
As of Apr 26
 -0.04 / -1.69%
Today’s Change
2.05
Today|||52-Week Range
4.80
+0.87%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$25.7M

Company Description

Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. The company's pipeline consists of ASP0113 Therapeutic CMV Vaccine, CyMVectin Prophylactic CMV Vaccine and VL-2397 Antifungal. Vical was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

Contact Information

Vical, Inc.
10390 Pacific Center Court
San Diego California 92121-4340
P:(858) 646-1100
Investor Relations:
(858) 646-1127

Employees

Shareholders

Individual stakeholders19.90%
Other institutional13.27%
Mutual fund holders12.24%

Top Executives

Vijay B. SamantPresident, Chief Executive Officer & Director
Keith D. HallVice President-Operations
Anthony Alan RamosChief Accounting Officer & Vice President-Finance
Larry SmithVice President-Vaccine Research
Mammen P. MammenVice President-Clinical Vaccines